COMBINATION OF SACUBITRIL AND VALSARTAN: POTENTIAL TREATMENT FOR PEDIATRIC HEART FAILURE

The PARADIGM-HF (Prospective comparison of angiotensin receptor antagonist (Valsartan) and neprilysin inhibitor (Sacubitril) (ARNi) with angiotensin converting enzyme inhibitor (ACEi) to determine impact on Global Mortality and Morbidity in Heart Failure) trial, has demonstrated that ARNi is superior to enalapril in reducing the risks of both sudden cardiac death and death from worsening HF. This novel combination of drugs, ARNi is also shown to reduce the risk of hospitalization and progression of HF in adults. However, the benefit of ARNi in pediatric HF patients is unknown.In this review, we discuss the pathophysiology of HF and the potential role of ARNi in pediatric HF patients